Your browser doesn't support javascript.
loading
In vitro quality of amotosalen-UVA pathogen-inactivated mini-pool plasma prepared from whole blood stored overnight.
Ravanat, Catherine; Dupuis, Arnaud; Marpaux, Nadine; Naegelen, Christian; Mourey, Guillaume; Isola, Herve; Laforêt, Michel; Morel, Pascal; Gachet, Christian.
Afiliación
  • Ravanat C; Université de Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, Strasbourg, France.
  • Dupuis A; Université de Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, Strasbourg, France.
  • Marpaux N; EFS Bourgogne-Franche-Comté, UMR1098, Besançon, France.
  • Naegelen C; EFS Bourgogne-Franche-Comté, UMR1098, Besançon, France.
  • Mourey G; EFS Bourgogne-Franche-Comté, UMR1098, Besançon, France.
  • Isola H; Université Bourgogne Franche Comté, INSERM, EFS Bourgogne-Franche-Comté, UMR1098, Besançon, France.
  • Laforêt M; Université de Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, Strasbourg, France.
  • Morel P; Université de Strasbourg, INSERM, EFS Grand-Est, BPPS UMR-S1255, FMTS, Strasbourg, France.
  • Gachet C; EFS Bourgogne-Franche-Comté, UMR1098, Besançon, France.
Vox Sang ; 113(7): 622-631, 2018 Oct.
Article en En | MEDLINE | ID: mdl-30079963
BACKGROUND AND OBJECTIVES: Small batch-pooled (mini-pool) whole blood (WB)-derived plasma could be an alternative cost-effective source of therapeutic plasma (TP), but carries an increased risk of transfusion-transmitted infection due to exposure of the recipient to several donors. This risk can be mitigated by inactivation of pathogens susceptible to the amotosalen-UVA (AUVA)-treatment. We evaluated the conservation of coagulation factors in AUVA-plasma prepared from WB stored overnight under routine operating conditions, to determine its therapeutic efficacy. Thrombin generation (TG) by the AUVA-plasma was used to provide an integrated measure of the hemostatic capacity. MATERIALS AND METHODS: WB-donations (~450 ml) stored overnight were processed to prepare five leucocyte-depleted plasma mini-pools (1300 ml), which were divided into two parts and treated with AUVA. Each mini-pool yielded six AUVA-plasma units (200 ml) which were frozen (-25°C) within 19 h of WB-collection. Their hemostatic quality was evaluated before and after treatment for up to 12 months of storage. RESULTS: Immediately after AUVA-treatment, the regulatory criteria for FVIII activity and fibrinogen content were met. As compared to untreated plasma there was a reduction in fibrinogen (14%), FV (9%), FVII (25%) and FVIII (32%). However, TG was similar in treated and untreated plasma at all-time-points. CONCLUSIONS: Frozen WB-derived AUVA-plasma prepared from mini-pools within 19 h of WB-collection met the quality standards required for TP and retained hemostatic capacity for up to 12 months. This product could provide a cost-effective convenient substitute for apheresis plasma.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Plasma / Furocumarinas / Conservación de la Sangre Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Vox Sang Año: 2018 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Plasma / Furocumarinas / Conservación de la Sangre Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Vox Sang Año: 2018 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Reino Unido